Approximately two-thirds of red blood cell transfusions are administered in the perioperative period, most by anaesthetists. In addition, a considerable proportion of the platelets and plasma are given to surgical patients.
Traditional transfusion practices are being reevaluated, primarily because of the fear of transfusion-transmitted disease. More conservative transfusion practices can also be attributed to concerns about the immunomodulatory effects of homologous transfusion. Although the mechanism is unclear, cancer patients who are transfused perioperatively have a worse prognosis than those with similar pathology who are not transfused. In addition, homologous transfusion may impair host defenses against bacterial infection and increase the risk of postoperative infection, t Most recommendations for current transfusion practices are based on the statements of the Consensus Conferences on Perioperative Red Blood Cell Transfusion 2 Platelet Therapy, 3 and Fresh Frozen Plasma 4 sponsored by the National Heart, Lung and Blood Institute. While these recommendations are the best available, further research is needed to provide a more scientific basis for transfusion practices.
The introduction of plastic bags and tubing in the 1950s led to the development of component therapy in the 1960s. The contemporary transfusion service can now provide 25 or more different blood products. Reliance on component therapy has led to more efficient utilization of the blood supply. Without fractionation, specific components will not be available when needed. Administration of unnecessary components is also avoided. Since the storage requirements for components differ, separation also permits each to be stored at optimal temperature to ensure maximal therapeutic benefit.
There has been a resurgence of interest in the use of fresh whole, blood, especially related-donor transfusion in cardiac surgery patients. 5 However, the identification of fatal graft-versus-host disease in several nonimmunocompromised patients has tempered this enthusiasm. 6 While irradiation of donor blood may eliminate this problem by inactivating lymphocytes responsible for the disorder, it is unlikely that the use of fresh whole blood will become widespread because of the logistics of collection and testing as well as the lack of proven efficacy. 7
Indications for red blood cell transfusion It has been traditional for anaesthetists to insist that patients have haemoglobin (Hb) concentrations of 10 g-dl-I or greater. 8 This arbitrary "10/30 rule" was based on theory and custom, not clinical or experimental evidence. Although extensive clinical experience has shown that patients with lower Hb levels can safely undergo anaesthesia and surgery, little information is available in the literature to substantiate the safety of anaesthetizing anaemic patients. 9
When deciding whether to transfuse, the physician must consider first the aetiology of the anaemia and whether it is acute or chronic. Acute blood loss triggers a number of compensatory mechanisms designed to maintain blood flow to vital organs, especially the heart and brain. These mechanisms include stimulation of the adrenergic nervous system, release of vasoactive hormones, hyperventilation, reabsorption of fluid from the interstitium into the vascular space, a shift of fluid from the intracellular to the extracellular compartment, and renal conservation of water and electrolytes. ,o Acute blood loss has profound effects on cardiac output, the primary determinant of tissue perfusion. Cardiac output is directly proportional to the venous return to the right side of the heart (preload). Preload increases during acute blood loss as a result of adrenergically mediated venoconstriction of the systemic venules and small veins. Mobilization of blood sequestered in this circulatory bed, which can represent 50% or more of the total blood volume, results in an increase in stroke volume. Heart rate also increases as a result of sympathetic nervous system stimulation. If blood loss continues, constriction of the vascular sphincters in the circulatory beds of the skin, skeletal muscle, kidney, and splanchnic viscera occurs. These mechanisms can restore cardiac output to or toward normal within 60-120 sec, unless blood loss exceeds the ability of the organism to compensate.
In chronically anaemic patients, cardiac output does not change until the Hb decreases to approximately 7 g. dl-i. ~l The cardiac output is then increased primarily by augmentation of stroke volume, not tachycardia.
When an increase in cardiac output is not possible or is undesirable, as in patients with coronary artery disease, transfusion may be indicated at higher Hb levels than in fit, young patients. How is the clinician to determine the appropriate "transfusion trigger" for an individual patient? A number of variables must be considered, not only the Hb value. Other determinants of tissue oxygen delivery are the inspired oxygen concentration and pulmonary gas exchange. The oxygen consumption must also be taken into account.
In the ideal 70 kg subject at rest, total body oxygen consumption approximates 250 ml and oxygen delivery 1000 ml per minute. The oxygen extraction ratio is thus 25%, indicative of a four-fold reserve. An oxygen extraction ratio of greater than 50-60% has been suggested as a valid indicator of the need for red blood cell transfusion, based on animal studies. '2"~3 These values correspond to haematocrits (Hct) of 10-15%. The absence of morbidity or mortality in normal, unanaesthetized, minimally stressed animals cannot be extrapolated to clinical practice. However, anecdotal reports of survival of severely anaemic patients support these observations. 14 The advent of invasive monitoring techniques has made possible the measurement of all variables which contribute to oxygen delivery and consumption. Cannulation of a peripheral artery provides access to arterial blood for gas determinations. Sampling of blood from a balloon-tipped pulmonary artery catheter provides true mixed-venous blood concentrations and the addition of a thermistor probe permits the determination of cardiac output by the thermodilution technique. Thus, all the determinations necessary to calculate oxygen delivery and the oxygen extraction ratio are available -at minimal risk. While it is neither necessary nor practical to place these invasive monitors in the vast majority of patients who may require transfusion, they should be used in assessing the need for red blood cell administration when indicated.
Red blood cells should be administered to increase oxygen carrying capacity, not for volume expansion, wound healing, or to improve "well-being." When anaemia is the result of acute blood loss, administration of acellular fluids constitutes initial therapy. Restoration of intravascular volume is far more important than transfusion to any arbitrary Hb level. Adequate oxygen carrying capacity can be met by a Hb level of 7 g.dl-t in most patients if intravascular volume is maintained. 2 In some patients lower Hb levels are well tolerated. Animal studies suggest that wound healing may be impaired at haematocrits (Hct) <15%. There is no evidence that anaemia increases the frequency or severity of postoperative infection or prolongs recovery in surgical patients. 2
Administration of platelets and plasma
There are two clinical situations in which decisions regarding administration of platelets and plasma must often be made: cardiac surgery and massive transfusion. In neither case is prophylactic administration of either component justified.
Patients undergoing cardiopulmonary bypass exhibit decreased platelet counts and thrombocytopathy during and after surgery. The exact aetiology of the platelet defect remains unclear. However, it has been shown that prophylactic administration of homologous platelets is of no value, t5 There is limited data to support the administration of platelet-rich plasma obtained by plasmapheresis prior to surgery, t6 '17 There are no data to justify the prophylactic administration of plasma.
In patients receiving large volumes of red blood cells, so-called massively transfused patients, clinical evaluation must be combined with laboratory studies. In the absence of clinical bleeding, laboratory values alone must not determine therapy. Conversely, in the face of on-going blood loss, administration of platelets and/or plasma may be indicated prior to availability of the results of laboratory tests. The most useful and most readily obtainable laboratory test for predicting bleeding in the massively transfused patient is the platelet count. 's'~9 Additional tests of value are the fibrinogen level, prothrombin time (PT), and activated partial thromboplastin time (aPTT).
There is no justification for the prophylactic administration of platelets 2~ or fresh frozen plasma (FFP) 21 in massively transfused patients. The guidelines set forth in the NIH consensus conference statements 3'4 should be followed. It must be remembered that coagulopathy in patients receiving massive transfusion correlates more closely with the duration of the volume deficit than with the total volume of blood transfused. 22 Therefore, the most important factor in preventing coagulopathy is early, adequate resuscitation.
A logical approach to evaluation of "abnormal" bleeding is to consider whether it is the result of trauma, transfusion or preexisting disease. Trauma includes that inflicted by the surgeon as well as wounds sustained outside the operating room. Surgical haemostasis is the cure for this type of bleeding.
Transfusion-associated bleeding can be the result of a dilutional coagulopathy or of a haemolytic transfusion reaction. Dilutional coagulopathy is unlikely unless transfusion exceeds 1.5 times the blood volume. Determination of the platelet count, PT, aPTT and fibrinogen level will assist in diagnosis and treatment.
Most haemolytic transfusion reactions are the result of improper identification of the patient by the transfusionist, and not of clerical errors in the laboratory. Oozing, hypotension and haemoglobinuria may indicate a haemolyric transfusion reaction. If such a reaction is suspected, the transfusion should be discontinued, identifying information verified, and the laboratory notified immediately. The simplest screening test is examination of a centrifuged blood sample for free plasma Hb. If there is no plasma discoloration, a serious haemolytic reaction is unlikely. On rare occasions haemolysis is the result of mixing of red blood cells with hypotonic solutions. Therefore, if the plasma is discoloured, all intravenous solution containers should be examined to ensure that a hypotonic solution was not used.
Coexisting coagulopathies may be congenital or acquired. Fortunately, most congenital disorders will be identified preoperatively. Therapy for these patients should be determined in consultation with a haematologist. Liver disease is the cause of many acquired coagulopathies. When administration of FFP is necessary, the minimal effective treatment in adults is often 600 to 2000 mi administered over a short period of time. 23 
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